Clinical Trials Browser

Interventional × Somatostatinoma × Bevacizumab × Clear all

NCT01525082 2024-02-06

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Phase 2 Completed

20 enrolled 15 charts

EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

Phase 2/3 Terminated

36 enrolled 14 charts

EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT01010126 2019-01-25

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Phase 2 Completed

252 enrolled 20 charts

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Somatostatinoma